MAPT and Alzheimer disease: Essentially all clinical trials in the last two decades (except for the recent controversial Aducanumab and Lecanemab) that targeted key pathological hallmarks of AD including amyloid plaques, Tau protein, and neuroinflammation ended without success [3], indicating that we still lack a complete understanding of the pathophysiology of this devasting disease.